Skip to main content
. 2017 Mar 7;7:43920. doi: 10.1038/srep43920

Figure 4. The effects of each of treatment approaches on post-MI remodeling.

Figure 4

(a) Representative photomicrographs of Mallory-stained cross-sections from each group (magnification, 10×; scale bars: 1 mm) on day 56. (b) The quantitative data of the infarct thickness. Sham + KLH, n = 5; Sham + Ang II vaccine, n = 5; MI + KLH, n = 11; MI + Ang II vaccine, n = 14; MI + Ang II vaccine (post-MI), n = 10; MI + losartan, n = 7. (c) A representative photomicrograph of the FITC-conjugated WGA staining of the non-infarct area (magnification 400×; scale bars: 50 μm) and (d) a quantitative comparison of the cross-sectional size of the cardiomyocytes in each group on day 56. Sham + KLH, n = 4; Sham + Ang II vaccine, n = 4; MI + KLH, n = 6; MI + Ang II vaccine, n = 7; MI + Ang II vaccine (post-MI), n = 6; MI + losartan, n = 7. *p < 0.05 by the Tukey–Kramer post hoc test. (e) A representative photomicrograph of CD68 immunostaining (magnification 200×; scale bars: 100 μm) and (f) the number of infiltrating macrophages (CD68-positive cells) in the peri-infarct zone on day 56. Sham + KLH, n = 5; Sham + Ang II vaccine, n = 5; MI + KLH, n = 6; MI + Ang II vaccine, n = 6; MI + Ang II vaccine (post-MI), n = 6; MI + losartan n = 7. *p < 0.05 by the Tukey–Kramer post hoc test. (g) The cardiac collagen level on day 56. Sham + KLH, n = 4; Sham + Ang II vaccine, n = 5; MI + KLH, n = 8; MI + Ang II vaccine, n = 12; MI + Ang II vaccine (post-MI), n = 7; MI + losartan, n = 6. *p < 0.05 by the Tukey–Kramer post hoc test. (h) The plasma BNP-45 level on day 56. Sham + KLH, n = 4; Sham + Ang II vaccine, n = 5; MI + KLH, n = 10; MI + Ang II vaccine, n = 8; MI + Ang II vaccine (post-MI), n = 7; MI + losartan, n = 7. *p < 0.05 by the Tukey–Kramer post hoc test.